US Corporate Distress Financial Stress SEC Filings — September 23, 2026

Completed a private placement of 350,000 shares and warrant exercises on September 16, 2026, which the company believes cures the Publicly Held Shares deficiency, providing a potential near-term lifeline

Stock continues trading on OTCQB Venture Market, maintaining some liquidity and accessibility for investors despite Nasdaq suspension

No insider purchases or capital allocation actions reported, indicating management is not backing the stock with personal capital or corporate buybacks

Met the 20 consecutive trading day bid price requirement by August 31, 2026 after a 1-for-12 reverse split, showing temporary compliance capability

Delisting becomes effective ten days after Form 25 filing, creating a known timeline for final OTC migration without ambiguity

Submitted a formal request for reconsideration based on a mistake of material fact, introducing a potential legal avenue to reverse delisting

No forward-looking guidance or revenue forecasts provided, leaving investors without a recovery roadmap

No insider trading activity reported in the filing, suggesting management is not signaling confidence through stock purchases

Nasdaq suspension since April 14, 2026, with a critical October 5, 2026 deadline to demonstrate a $1.00 closing bid price for 10 consecutive days; failure means permanent delisting

Nasdaq will file Form 25 to complete delisting; no cure or reconsideration process mentioned, making OTC trading permanent

The 1-for-12 reverse stock split caused publicly held shares to fall below 500,000, directly triggering the Publicly Held Shares deficiency—a self-inflicted compliance failure

Trading suspended since June 25, 2026, and now on OTC Market with likely reduced liquidity and institutional investor exclusion

Filing lacks any period-over-period revenue, margin, or cash flow comparisons, obscuring the company's operational health and ability to sustain compliance

No insider purchases or sales reported, indicating management may lack conviction in the company's turnaround prospects

Only 12 days from the filing date (September 23) to the October 5 deadline for bid price compliance, creating extreme time sensitivity

No dividends, buybacks, or capital allocation actions reported, suggesting the company is conserving cash or lacks financial flexibility

The request for reconsideration based on a mistake of material fact could lead to Nasdaq reversing the delisting decision, creating a potential 100%+ upside if successful

The completion of a 350,000-share private placement and warrant exercises on September 16 suggests some investor confidence and capital infusion, potentially stabilizing the stock

If the stock maintains a $1.00 closing bid for 10 consecutive days by October 5, it could regain full Nasdaq compliance and trigger a re-rating

The stock continues trading on OTCQB, allowing nimble investors to accumulate positions before a potential Nasdaq reinstatement

Once delisting is complete and the stock is fully on OTC, distressed debt or turnaround investors may find entry points if the company has underlying assets or cash

While no insider buying was reported, there is also no insider selling, which could indicate insiders are holding positions in anticipation of a recovery

Given the low float post-reverse split and extreme distress, any positive news on reconsideration could trigger a short squeeze

Both SCWorx and Aditxt are micro-cap companies (<$50M market cap) that failed to maintain Nasdaq listing standards, highlighting a broader trend of small-cap healthcare/tech firms struggling with compliance post-reverse splits

SCWorx's reverse split solved the bid price issue but created a publicly held shares deficiency, demonstrating how reverse splits can inadvertently trigger new compliance failures

Neither filing reported insider purchases or sales, suggesting management teams in distressed micro-caps may be unwilling or unable to signal confidence through personal investment

Both companies now trade on OTC markets, which typically leads to reduced liquidity, higher volatility, and exclusion from institutional portfolios—a common distress pattern

Neither company provided forward-looking statements or financial forecasts, leaving investors without a recovery narrative and amplifying uncertainty

Monitor whether the stock maintains a $1.00 closing bid for 10 consecutive trading days by October 5, 2026; this is a binary event for Nasdaq reinstatement

Watch for Nasdaq's response to the request for reconsideration based on a mistake of material fact; a positive ruling could reverse delisting

Monitor trading activity on OTCQB for signs of accumulation or distribution ahead of the October 5 deadline

Track when Nasdaq files Form 25 with the SEC; delisting becomes effective 10 days after, marking the final transition to OTC

Watch for any press releases or 8-K filings regarding business operations, funding, or strategic alternatives after delisting

Monitor SEC Form 4 filings for any insider purchases or sales in the days following the September 23 filing, which would signal management conviction

Delisting events often trigger shareholder litigation; monitor for any class action filings or derivative suits